Programmed Death Ligand-1 (PD-L1) Is an Independent Negative Prognosticator in Western-World Gallbladder Cancer.
PD-L1
biomarkers
gallbladder cancer
gastrointestinal neoplasms
immune evasion
liver neoplasms
programmed cell death ligand-1
tumor
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
02 Apr 2021
02 Apr 2021
Historique:
received:
04
01
2021
revised:
23
03
2021
accepted:
26
03
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Inhibition of the programmed cell death protein-1/ligand-1 (PD-1/PD-L1) axis has opened a new era in the treatment of solid cancers. However, there is no data on the expression and relevance of PD-L1 in Western gallbladder cancer (GBC). We assessed PD-L1 immunohistochemically in 131 GBC patients as Tumor Proportion Score (TPS), Immune Cell Score (IC) and Combined Positivity Score (CPS). Tumor cells expressed PD-L1 in a subset of 14.7% GBC patients at a TPS cut-off of 1%. Higher PD-L1 levels above 10% and 25% TPS were reached in 4.7% and 3.1% of GBC cases, respectively. At a 10% cut-off, TPS was associated with distinct histomorphological subtypes and correlated with poor tumor differentiation. Survival analysis revealed a TPS above 10% to be a highly significant and independent negative prognosticator in GBC. PD-L1 expression was associated with increased CD4
Identifiants
pubmed: 33918309
pii: cancers13071682
doi: 10.3390/cancers13071682
pmc: PMC8038183
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Methods Mol Biol. 2010;664:27-35
pubmed: 20690049
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Virchows Arch. 2020 Jun;476(6):871-880
pubmed: 31838585
J Thorac Oncol. 2018 Mar;13(3):447-453
pubmed: 29246835
Clin Cancer Res. 2014 Oct 1;20(19):5064-74
pubmed: 24714771
J Hematol Oncol. 2019 Sep 5;12(1):92
pubmed: 31488176
Z Gastroenterol. 2016 May;54(5):426-30
pubmed: 27171333
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Mod Pathol. 2015 Dec;28(12):1535-44
pubmed: 26403784
J Immunother Cancer. 2020 Sep;8(2):
pubmed: 32900861
Br J Cancer. 2015 Nov 3;113(9):1343-9
pubmed: 26461054
Cancers (Basel). 2020 Mar 10;12(3):
pubmed: 32164163
Onco Targets Ther. 2019 Jul 08;12:5389-5393
pubmed: 31360065
Clin Epidemiol. 2014 Mar 07;6:99-109
pubmed: 24634588
J Clin Invest. 2015 May;125(5):2046-58
pubmed: 25866972
Clin Cancer Res. 2018 Mar 15;24(6):1287-1295
pubmed: 29298798
Sci Rep. 2017 Mar 07;7:42929
pubmed: 28266500
PLoS One. 2017 Oct 19;12(10):e0186192
pubmed: 29049375
J Immunother Cancer. 2019 Nov 15;7(1):305
pubmed: 31730010
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Gut. 2017 May;66(5):794-801
pubmed: 26801886
Diagn Pathol. 2018 Feb 9;13(1):12
pubmed: 29426340
Clin Cancer Res. 2020 Feb 15;26(4):970-977
pubmed: 31615933
Front Pharmacol. 2017 Aug 23;8:561
pubmed: 28878676
J Pathol Transl Med. 2020 Mar;54(2):154-164
pubmed: 32028754
Cancer Immunol Res. 2019 Oct;7(10):1700-1713
pubmed: 31387897
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Mol Cancer. 2018 Aug 23;17(1):129
pubmed: 30139382
Adv Ther. 2019 Oct;36(10):2600-2617
pubmed: 31432460
Mol Cancer. 2019 Nov 6;18(1):155
pubmed: 31690319
BMC Cancer. 2018 May 11;18(1):556
pubmed: 29751789
Cancer Treat Res Commun. 2020;25:100239
pubmed: 33271494
J Oncol. 2015;2015:967472
pubmed: 26421012
Am J Cancer Res. 2020 Mar 01;10(3):727-742
pubmed: 32266087
N Engl J Med. 2019 Nov 21;381(21):2020-2031
pubmed: 31562796
Br J Cancer. 2019 May;120(10):1003-1006
pubmed: 30967647
BMC Cancer. 2018 Jul 28;18(1):766
pubmed: 30055582
Pathologe. 2018 Nov;39(6):498-519
pubmed: 30367225
Diagn Pathol. 2019 May 8;14(1):36
pubmed: 31068195
Oncol Rep. 2021 Mar;45(3):835-845
pubmed: 33469677
Sci Transl Med. 2016 Mar 2;8(328):328rv4
pubmed: 26936508
Cancer Discov. 2020 Aug;10(8):1086-1087
pubmed: 32576590
Clin Exp Hepatol. 2019 May;5(2):93-102
pubmed: 31501784
J Pathol. 2020 Nov;252(3):239-251
pubmed: 32710569
Oncoimmunology. 2016 Sep 20;5(11):e1235107
pubmed: 27999753
Adv Immunol. 2006;90:51-81
pubmed: 16730261
Histopathology. 2018 Oct;73(4):622-633
pubmed: 29882997
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
Oncotarget. 2017 Dec 19;9(3):4120-4133
pubmed: 29423109
J Immunother. 2020 Oct;43(8):236-243
pubmed: 32804915
Lancet Gastroenterol Hepatol. 2019 Aug;4(8):611-621
pubmed: 31109808